BSE Live
Mar 11, 16:01Prev. Close
1813.00
Open Price
1817.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 11, 15:59Prev. Close
1812.80
Open Price
1823.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1825.90 (210)
| Key Financial Ratios of Sun Pharmaceutical Industries (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 17.80 | 11.90 | 7.00 | -0.40 | 8.92 | |
| Diluted EPS (Rs.) | 17.80 | 11.90 | 7.00 | -0.40 | 8.92 | |
| Cash EPS (Rs.) | 23.01 | 18.58 | 13.72 | 5.21 | 11.36 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 101.45 | 98.76 | 98.98 | 102.48 | 104.36 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 101.45 | 98.76 | 98.98 | 102.48 | 104.36 | |
| Dividend / Share(Rs.) | 16.00 | 13.50 | 11.50 | 10.00 | 7.50 | |
| Revenue from Operations/Share (Rs.) | 95.88 | 84.50 | 86.74 | 64.96 | 53.36 | |
| PBDIT/Share (Rs.) | 29.85 | 25.23 | 28.14 | 16.11 | 12.86 | |
| PBIT/Share (Rs.) | 24.69 | 18.56 | 21.47 | 10.48 | 10.42 | |
| PBT/Share (Rs.) | 20.97 | 14.38 | 7.26 | 1.28 | 8.97 | |
| Net Profit/Share (Rs.) | 17.85 | 11.91 | 7.05 | -0.42 | 8.92 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 31.13 | 29.85 | 32.44 | 24.80 | 24.10 | |
| PBIT Margin (%) | 25.75 | 21.96 | 24.75 | 16.13 | 19.52 | |
| PBT Margin (%) | 21.86 | 17.01 | 8.36 | 1.96 | 16.81 | |
| Net Profit Margin (%) | 18.61 | 14.09 | 8.12 | -0.64 | 16.71 | |
| Return on Networth / Equity (%) | 17.59 | 12.06 | 7.11 | -0.40 | 8.54 | |
| Return on Capital Employed (%) | 23.57 | 12.15 | 15.79 | 8.20 | 8.15 | |
| Return on Assets (%) | 9.89 | 6.96 | 4.12 | -0.24 | 5.48 | |
| Total Debt/Equity (X) | 0.45 | 0.47 | 0.32 | 0.20 | 0.26 | |
| Asset Turnover Ratio (%) | 0.55 | 0.49 | 0.51 | 0.39 | 0.33 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.03 | 3.36 | 1.97 | 0.96 | 1.45 | |
| Quick Ratio (X) | 0.82 | 2.59 | 1.49 | 0.62 | 1.07 | |
| Inventory Turnover Ratio (X) | 6.38 | 1.20 | 1.40 | 1.40 | 1.31 | |
| Dividend Payout Ratio (NP) (%) | 84.38 | 101.39 | 149.00 | -2,159.12 | 72.86 | |
| Dividend Payout Ratio (CP) (%) | 65.45 | 64.99 | 76.53 | 172.71 | 57.18 | |
| Earnings Retention Ratio (%) | 15.62 | -1.39 | -49.00 | 2,259.12 | 27.14 | |
| Cash Earnings Retention Ratio (%) | 34.55 | 35.01 | 23.47 | -72.71 | 42.82 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 426,430.49 | 399,514.79 | 243,046.57 | 223,821.71 | 149,635.45 | |
| EV/Net Operating Revenue (X) | 18.54 | 19.70 | 11.68 | 14.36 | 11.69 | |
| EV/EBITDA (X) | 59.54 | 66.00 | 36.00 | 57.90 | 48.49 | |
| MarketCap/Net Operating Revenue (X) | 18.10 | 19.18 | 11.33 | 14.08 | 11.20 | |
| Retention Ratios (%) | 15.61 | -1.39 | -49.00 | 2,259.12 | 27.13 | |
| Price/BV (X) | 17.11 | 16.41 | 9.93 | 8.93 | 5.73 | |
| Price/Net Operating Revenue | 18.10 | 19.18 | 11.33 | 14.08 | 11.20 | |
| Earnings Yield | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
11.03.2026
10.03.2026
10.03.2026
Polycab, KEI Industries shares decline up to 6% on rising copper prices
10.03.2026
Ballarpur Ind Standalone December 2025 Net Sales at Rs 10.77 crore, up 959.5% Y-o-Y
03.02.2026
Sun Pharma Consolidated December 2025 Net Sales at Rs 15,520.54 crore, up 13.49% Y-o-Y
03.02.2026
Sun Pharma Standalone December 2025 Net Sales at Rs 5,687.77 crore, down 8.14% Y-o-Y
11.11.2025
Sun Pharma Standalone September 2025 Net Sales at Rs 4,548.11 crore, down 11.3% Y-o-Y
01.08.2025
Sun Pharma Consolidated June 2025 Net Sales at Rs 13,851.40 crore, up 9.47% Y-o-Y
03.02.2026
Sun Pharma Consolidated December 2025 Net Sales at Rs 15,520.54 crore, up 13.49% Y-o-Y
03.02.2026
Sun Pharma Standalone December 2025 Net Sales at Rs 5,687.77 crore, down 8.14% Y-o-Y
11.11.2025
Sun Pharma Standalone September 2025 Net Sales at Rs 4,548.11 crore, down 11.3% Y-o-Y
01.08.2025
Sun Pharma Consolidated June 2025 Net Sales at Rs 13,851.40 crore, up 9.47% Y-o-Y
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities